Histone deacetylase inhibitors
AssigneeErrant Gene Therapeutics, LLC
InventorsHsuan-Yin Lan-Hargest, Robert J. Kaufman, Norbert L. Wiech
Life of this patent
Estimating the term…
Abstract
Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, genetic disorders, e.g. Huntington's disease and spinal muscular atrophy and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.
Claims1
A method of treating spinal muscular atrophy in a mammal comprising administering to the mammal an effective amount of 7-phenyl-2,4,6-heptatrienoic acid.
Dependencies are inferred from the claim text.